Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Immunology
Impact-faktor: 1.404 5-jähriger Impact-Faktor: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472

Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.140
10 pages

The Identification and Development of Specific Monoclonal Antibodies to Squamous Cell Carcinoma

Myron Arlen
Department of Surgery, North Shore University Hospital, Manhasset, NY and International Bioimmune Systems, Great Neck, NY
Al Tsang
Dept. of Immunology, Medical University of South Carolina
Joseph Scherrer
International Bioimmune Systems, Great Neck, NY
Joyce Wolf
International Bioimmune Systems, Great Neck, NY
Olga Saric
International Bioimmune Systems, Great Neck, NY


We have developed specific monoclonal antibodies to immunogenic glycoproteins expressed selectively on the cell membrane of squamous cell malignancies. These proteins serve to act as tumor markers that characterize this malignancy; there has be no evidence of cross reactivity to normal epithelial cells. Analysis of patterns of expression reveals that those membrane proteins identified by monoclonals AD7 and 5C6 appear early in cellular transformation to malignancy. At such a time, immunohistochemical recognition is seen in the presence of genotypic alterations, yet phenotypic changes may not be apparent. Of additional interest is that these monoclonal antibodies exhibit strong ADCC allowing the tumor proteins to not only serve as a marker of malignancy but as a target for therapeutic destruction.

Articles with similar content:

Dendritic Cell-Derived Exosomes as Cell-Free Peptide-Based Vaccines
Critical Reviews™ in Immunology, Vol.25, 2005, issue 3
Julien Taieb, Nathalie Chaput, Laurence Zitvogel
Resistance to Cell Death and Its Modulation in Cancer Stem Cells
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 3-4
Ahmad R. Safa
Toll-like Receptor Modulation in Head and Neck Cancer
Critical Reviews™ in Immunology, Vol.28, 2008, issue 3
Barbara Wollenberg, Sandra Wulff, Ralph Pries
The Role of Oncogenic DNA Viruses in Penile Cancer Development
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 4
Silvia Maria Baeta Cavalcanti, Katia Cristina da Silva, Willker Menezes da Rocha
Autoimmunity and the Immunotherapy of Cancer: Targeting the "Self" to Destroy the "Other"
Critical Reviews™ in Immunology, Vol.20, 2000, issue 6
Nicholas P. Restifo, Willem W. Overwijk